Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Gao Bipolar Spectrum Lithium/Quetiapine Study

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by University Hospital Case Medical Center
Information provided by (Responsible Party):
Dr. Keming Gao, University Hospital Case Medical Center Identifier:
First received: January 25, 2012
Last updated: October 10, 2014
Last verified: October 2014

This is a 4-month randomized open-label comparative safety, tolerability, and effectiveness trial of Lithium versus Quetiapine for subjects presenting in any phase of Bipolar who currently require a medication change for their illness. Stratified randomization will reduce bipolar type I , bipolar type II , or sub-threshold imbalance across cells. The enrollment goal is 60 subjects, over 24 months from initial regulatory approval. The primary outcome is the difference between lithium and quetiapine in the time to 'all cause' medication discontinuation.

Condition Intervention Phase
Bipolar Disorder
Drug: Lithium
Drug: Quetiapine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparative Safety, Tolerability, and Effectiveness of Lithium Versus Quetiapine in Patients Across the Spectrum of Bipolar Disorder

Resource links provided by NLM:

Further study details as provided by University Hospital Case Medical Center:

Primary Outcome Measures:
  • Time to study discontinuation [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
    The time for discontinuation due to all causes will be measured and used as the primary outcome measure.

Secondary Outcome Measures:
  • Lithium vs. Quetiapine effects on general cardiovascular disease risk and role effects on general cardiovascular disease risk and role impairment [ Time Frame: Week 16 ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: January 2012
Estimated Study Completion Date: September 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Lithium Drug: Lithium
Lithium will be initiated at 300 mg per day and titrated in 300 mg increments every 7days as tolerated with blood lithium levels > 0.6mEq/L.
Other Names:
  • Lithium Carbonate
  • Eskalith
Active Comparator: Quetiapine Drug: Quetiapine
Quetiapine will be started at 50 mg per day at bedtime and titrated up to 300 mg as tolerated over 1 week.
Other Name: Seroquel


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Able to provide informed consent before beginning any study-specific procedures
  • Male and female patients at least 18 years of age
  • Meets Diagnostic and Statistical Manual -IV criteria for BPI, BP II, or National Comorbidity Survey-R criteria for sub-threshold BP with or without symptoms, in need of medication adjustment(s)
  • Willing to be randomized to either Lithium or Quetiapine
  • If a sexually active female of childbearing potential, be using a reliable method of contraception, such as oral contraceptive or long-term injectable or implantable hormonal contraceptive, double-barrier methods (e.g. condom and diaphragm, condom and foam, condom and sponge), intrauterine devices, and tubal ligation
  • Women with reproductive potential must have a negative urine pregnancy test

Exclusion Criteria:

  • Unwilling to comply with study requirements
  • Patients who have had severe adverse reaction to Lithium or Quetiapine
  • Patients who require inpatient care
  • Drug/alcohol dependence requiring immediate acute detoxification
  • Pregnancy as determined by serum pregnancy test or breastfeeding
  • History of nonresponse to Lithium at doses >900 mg ≥8 wks or to Quetiapine at doses of at least 300 mg/d ≥ 8 week for depression and at least 400-600 mg/d ≥ 4 wks for mania.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01526148

Contact: Toyomi Goto, MA 216-844-2862

United States, Ohio
University Hospitals Case Medical Center - Mood Disorders Program Recruiting
Cleveland, Ohio, United States, 44106
Contact: Toyomi Goto, M.A    216-844-2862   
Principal Investigator: Keming Gao, MD, PhD         
Sponsors and Collaborators
University Hospital Case Medical Center
Principal Investigator: Keming Gao, MD, PhD University Hospital Case Medical Center
  More Information

No publications provided

Responsible Party: Dr. Keming Gao, Director, Mood & Anxiety Clinic, University Hospital Case Medical Center Identifier: NCT01526148     History of Changes
Other Study ID Numbers: 09-11-01
Study First Received: January 25, 2012
Last Updated: October 10, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Bipolar Disorder
Affective Disorders, Psychotic
Mental Disorders
Mood Disorders
Lithium Carbonate
Antidepressive Agents
Antimanic Agents
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents processed this record on March 01, 2015